Cullen/Frost Bankers’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$95.5M Buy
103,850
+178
+0.2% +$180K 1.08% 23
2025
Q4
$111M Sell
103,672
-434
-0.4% -$415K 1.23% 19
2025
Q3
$79.4M Buy
104,106
+267
+0.3% +$199K 0.92% 27
2025
Q2
$80.9M Buy
103,839
+1,075
+1% +$835K 1.01% 24
2025
Q1
$84.9M Buy
102,764
+731
+0.7% +$608K 1.19% 23
2024
Q4
$78.8M Sell
102,033
-476
-0.5% -$394K 1.08% 24
2024
Q3
$90.8M Sell
102,509
-342
-0.3% -$307K 1.24% 19
2024
Q2
$93.1M Sell
102,851
-1,386
-1% -$1.11M 1.35% 15
2024
Q1
$81.1M Sell
104,237
-4,204
-4% -$2.99M 1.2% 20
2023
Q4
$63.2M Sell
108,441
-7,638
-7% -$4.46M 0.99% 24
2023
Q3
$62.3M Sell
116,079
-2,001
-2% -$1.03M 1.09% 20
2023
Q2
$55.4M Sell
118,080
-2,718
-2% -$1.14M 0.94% 24
2023
Q1
$41.5M Sell
120,798
-259
-0.2% -$87.3K 0.76% 29
2022
Q4
$44.3M Buy
121,057
+8,205
+7% +$2.91M 0.85% 30
2022
Q3
$36.5M Buy
112,852
+3,624
+3% +$1.15M 0.83% 28
2022
Q2
$35.4M Buy
109,228
+2,681
+3% +$805K 0.79% 28
2022
Q1
$30.5M Buy
106,547
+2,605
+3% +$670K 0.59% 39
2021
Q4
$28.7M Sell
103,942
-3,030
-3% -$768K 0.55% 49
2021
Q3
$24.7M Buy
106,972
+4,571
+4% +$1.13M 0.5% 53
2021
Q2
$23.5M Sell
102,401
-3,646
-3% -$732K 0.47% 55
2021
Q1
$19.8M Buy
106,047
+161
+0.2% +$31.5K 0.43% 64
2020
Q4
$17.9M Buy
105,886
+6,277
+6% +$937K 0.41% 68
2020
Q3
$14.7M Buy
99,609
+76,092
+324% +$11.8M 0.37% 75
2020
Q2
$3.86M Sell
23,517
-393
-2% -$60.3K 0.1% 175
2020
Q1
$3.32M Sell
23,910
-961
-4% -$132K 0.12% 160
2019
Q4
$3.27M Sell
24,871
-1,205
-5% -$140K 0.09% 184
2019
Q3
$2.92M Sell
26,076
-1,670
-6% -$186K 0.09% 190
2019
Q2
$3.07M Sell
27,746
-729
-3% -$85.8K 0.1% 182
2019
Q1
$3.69M Sell
28,475
-3,046
-10% -$370K 0.11% 162
2018
Q4
$3.65M Buy
31,521
+7,890
+33% +$881K 0.14% 156
2018
Q3
$2.54M Sell
23,631
-1,524
-6% -$152K 0.08% 183
2018
Q2
$2.15M Sell
25,155
-1,067
-4% -$87.6K 0.07% 190
2018
Q1
$2.03M Sell
26,222
-4,245
-14% -$342K 0.06% 203
2017
Q4
$2.57M Sell
30,467
-462
-1% -$39.3K 0.08% 182
2017
Q3
$2.65M Sell
30,929
-1,862
-6% -$153K 0.09% 180
2017
Q2
$2.7M Sell
32,791
-1,935
-6% -$158K 0.09% 180
2017
Q1
$2.92M Sell
34,726
-2,296
-6% -$184K 0.1% 169
2016
Q4
$2.72M Sell
37,022
-29,822
-45% -$2.22M 0.09% 174
2016
Q3
$5.37M Sell
66,844
-1,510
-2% -$121K 0.19% 134
2016
Q2
$5.38M Sell
68,354
-1,252
-2% -$94.3K 0.2% 129
2016
Q1
$5.01M Sell
69,606
-3,708
-5% -$281K 0.19% 127
2015
Q4
$6.18M Sell
73,314
-1,641
-2% -$136K 0.23% 119
2015
Q3
$6.27M Buy
74,955
+1,160
+2% +$97.9K 0.25% 112
2015
Q2
$6.16M Sell
73,795
-7,986
-10% -$609K 0.23% 121
2015
Q1
$5.94M Buy
81,781
+1,093
+1% +$77.8K 0.22% 124
2014
Q4
$5.57M Sell
80,688
-1,613
-2% -$109K 0.21% 130
2014
Q3
$5.34M Buy
82,301
+1,847
+2% +$117K 0.22% 126
2014
Q2
$5M Buy
80,454
+9,428
+13% +$563K 0.2% 133
2014
Q1
$4.18M Sell
71,026
-3,039
-4% -$170K 0.18% 141
2013
Q4
$3.78M Sell
74,065
-136,384
-65% -$6.83M 0.17% 146
2013
Q3
$10.6M Buy
210,449
+847
+0.4% +$44.3K 0.52% 65
2013
Q2
$10.3M Buy
+209,602
New +$11.4M 0.54% 56

Other funds holding LLY

Cullen/Frost Bankers's LLY Position: Q1 2026 in Review

Cullen/Frost Bankers increased its Eli Lilly (LLY) stake by 0.17% in Q1 2026, buying an estimated $180K and bringing the position to 103,850 shares worth $95.5M. The position accounts for 1.08% of the portfolio, ranked #23.

Cullen/Frost Bankers first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $111M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Cullen/Frost Bankers held 103,850 shares of Eli Lilly worth $95.5M as of Q1 2026.
  • Cullen/Frost Bankers bought 178 Eli Lilly shares in Q1 2026, an estimated $180K.
  • Eli Lilly made up 1.08% of Cullen/Frost Bankers's portfolio in Q1 2026, its #23 holding.
  • Cullen/Frost Bankers first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Cullen/Frost Bankers's Eli Lilly position peaked at $111M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.